| European Case Law Identifier: | ECLI:EP:BA:1987:T000786.19870916 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 16 September 1987 | ||||||||
| Case number: | T 0007/86 | ||||||||
| Application number: | 79850091.4 | ||||||||
| IPC class: | A61K 31/52 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | A | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease | ||||||||
| Applicant name: | DRACO | ||||||||
| Opponent name: | Napp | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | A class of chemical compounds defined only by a general structural formula having at least two variable groups does not specifically disclose each of the individual compounds which would result from the combination of all possible variants within such groups (following decisions T 12/81 OJ EPO 1982, 296 and T 181/82 OJ EPO 1984, 401, point 7 of the Reasons). | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Novelty of a specific compound from a generic formula First medical use Inventive step - Choice from numerous possibilities |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: | |||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t860007ex1.html
Date retrieved: 17 May 2021
18 references found.
Click X to load a reference inside the current page, click on the title to open in a new page.Offical Journal of the EPO
XOJ EPO SE 1/2021, p179 - Annex 1 - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2020)
XOJ EPO SE 1/2020, p174 - Annex 1 - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2019)
XOJ EPO SE 1/2019, p158 - XVI. - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2018)